Newsbenzinga
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
· Published
Article summary
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
An excerpt from the original article.
Comments —
Loading comments…